Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Csepregi, Antal ^a,b   Ebert, Matthias P A ^a,d   Röcken, Christoph ^a,c   Schneider Stock, Regine ^a,e   Hoffmann, Juliane ^a   Schulz, Hans Ulrich ^a   Roessner, Albert ^a   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b Hufeland Klinikum GmbH Bad Langensalza   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P16; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILE DUCT CANCER; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER TUMOR; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; TISSUE SECTION; CHEMISTRY; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 77953676683     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-317     Document Type: Article

References (34)

1. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. Continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003, 139:817-823.
2. Bosch X, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999, 19:271-285. 10.1055/s-2007-1007117, 10518307.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917. 10.1016/S0140-6736(03)14964-1, 14667750.
4. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and HBV: a prospective study of 22,707 men in Taiwan. Lancet 1981, 2:1129-1132. 10.1016/S0140-6736(81)90585-7, 6118576.
5. Wogan GN. Aflatoxin as a human carcinogen. Hepatology 1999, 30:573-575. 10.1002/hep.510300231, 10421671.
6. Colombo M. Hepatitis C virus and hepatocellular carcinoma. Semin Liver Dis 1999, 19:263-269. 10.1055/s-2007-1007116, 10518306.
7. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDJ4. Nature (Lond) 1993, 366:704-707.
8. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440. 10.1126/science.8153634, 8153634.
9. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond) 1994, 368:753-756.
10. Hui AM, Sakamoto M, Kanai Y, Ino Y, Gotoh M, Yokota J, Hirohashi S. Inactivation of p16INK4 in hepatocellular carcinoma. Hepatology 1996, 24:575-579. 10.1002/hep.510240319, 8781327.
11. Biden K, Young J, Buttenshaw R, Searle J, Cooksley G, Xu DB, Leggett B. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population. Hepatology 1997, 25:593-597. 10.1002/hep.510250317, 9049204.
12. Chaubert P, Gayer R, Zimmermann A, Fontolliet C, Stamm B, Bosman F, Shaw P. Germ-line mutations of the p16INK4(MTS1) gene occur in a subset of patients with hepatocellular carcinoma. Hepatology 1997, 25:1376-1381. 10.1002/hep.510250613, 9185756.
13. Baek MJ, Piao Z, Kim N-G, Park C, Shin E-C, Park J-H, Jung H-J, Kim CG, Kim H. p16 is a major inactivation target in hepatocellular carcinoma. Cancer 2000, 89:60-68. 10.1002/1097-0142(20000701)89:1<60::AID-CNCR9>3.0.CO;2-3, 10897001.
14. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC. 5' CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995, 1:686-692. 10.1038/nm0795-686, 7585152.
15. Matsuda Y, Ichida T, Matsuzawa J, Sugimura K, Asakura H. p16INK4 is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology 1999, 116:394-400. 10.1016/S0016-5085(99)70137-X, 9922321.
16. Kaneto H, Sasaki S, Yamamoto H, Itoh F, Toyota M, Suzuki H, Ozeki I, Iwata N, Ohmura T, Satoh T, Karino Y, Satoh T, Toyota J, Satoh M, Endo T, Omata M, Imai K. Detection of hypermethylation of the p16INK4a promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut 2001, 48:372-377. 10.1136/gut.48.3.372, 1760137, 11171828.
17. Li X, Hui A-M, Sun L, Hasegawa K, Torzilli G, Minagawa M, Takayama T, Makuuchi M. p16INK4a hypermethylation is associated with hepatitis virus infection, age, and gender in hepatocellular carcinoma. Clin Cancer Res 2004, 10:7484-7489. 10.1158/1078-0432.CCR-04-1715, 15569978.
18. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-9826. 10.1073/pnas.93.18.9821, 38513, 8790415.
19. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW. Methy-Light: a high-throughput assay to measure DNA methylation. Nucleic Acid Res 2000, 28:E32. 10.1093/nar/28.8.e32, 102836, 10734209.
20. Eads CA, Lord RV, Kurumboor SK, Wickramasinghe K, Skinner ML, Long TI, Peters JH, DeMeester TR, Danenberg KD, Danenberg PV, Laird PW, Skinner KA. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000, 60:5021-5026.
21. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954, 7:462-503. 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E, 13160935.
22. MacSween RNM, Burt AD, Portman BC, Ishak KG, Scheuer PJ, Anthony PP. Pathology of the liver. 2002, Edinburgh, London Churchill Livingstone.
23. Ishak K, Baptista A, Bianchi L, Cellea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RNM, Phillips MJ, Portmann BG, Poulsen H, Scheuer PJ, Schmid M, Thaler H. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:966-969.
24. Ebert MP, Yu J, Hoffmann J, Rocco A, Rocken C, Kahmann S, Muller O, Korc M, Sung JJ, Malfertheiner P. Loss of beta-catenin expression in metastatic gastric cancer. J Clin Oncol 2003, 21:1708-1714. 10.1200/JCO.2003.10.017, 12721245.
25. Ebert MPA, Mooney SH, Tonnes-Priddy L, Lograsso J, Hoffmann J, Chen J, Röcken C, Schulz H-U, Malfertheiner P, Lofton-Day C. Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers. Neoplasia 2005, 7:771-778. 10.1593/neo.05235, 1501884, 16207479.
26. Schneider-Stock R, Boltze C, Peters B, Höpfner T, Meyer F, Lippert H, Roessner A. Differences in loss of p16INK4 protein expression by promoter methylation between left- and right-sided primary colorectal carcinomas. Int J Oncol 2003, 23:1009-1013.
27. Shim Y-H, Yoon G-S, Choi H-J, Chung YH, Yu E. p16 hypermethylation in the early stage of hepatitis B virus-associated hepatocarcinogenesis. Cancer Lett 2003, 190:213-219. 10.1016/S0304-3835(02)00613-4, 12565176.
28. Norrie MWA, Hawkins NJ, Todd AV, Meagher AP, O'Connor TW, Ward RL. Inactivation of p16INK4a by CpG hypermethylation is not a frequent event in colorectal cancer. J Surg Oncol 2003, 84:143-150. 10.1002/jso.10310, 14598358.
29. Prall FP, Ostwald C, Weirich V, Nizze H. p16INK4a promoter methylation and 9p21 allelic loss in colorectal carcinomas: relation with immunohistochemical p16INK4a expression and tumor budding. Human Pathol 2006, 37:578-585.
30. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996, 85:27-37. 10.1016/S0092-8674(00)81079-X, 8620534.
31. Zindy F, Quelle DE, Roussel MF, Sherr CJ. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 1997, 15:203-211. 10.1038/sj.onc.1201178, 9244355.
32. Dai CY, Furth EE, Mick R, Koh J, Takayama T, Niitsu Y, Enders GH. p16INK4a expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation. Gastroenterology 2000, 119:929-942. 10.1053/gast.2000.17952, 11040180.
33. Palmqvist R, Rutegard JN, Bozoky B, Landberg G, Stenling R. Human colorectal cancers with an intact p16/cyclinD/pRb pathway have up-regulated p16 expression and decreased proliferation in small invasive tumor clusters. Am J Pathol 2000, 157:1947-1953.
34. Tsujie M, Yamamoto H, Tomita N, Sugita Y, Ohue M, Sakita I. Expression of tumor suppressor gene p16(INK4) products in primary gastric cancer. Oncology 2000, 58:126-136. 10.1159/000012089, 10705239.